Vapotherm Inc. Announces $30 Million Financing Round - Gilde Healthcare

Vapotherm Inc. Announces $30 Million Financing Round

November 24, 2015

EXETER, NH,– Vapotherm, Inc., announced today it closed a $30 million equity financing last month. The first tranche of $15 million closed on October 30, 2015, and the second tranche is scheduled to close in September 2016. Arnerich Massena led the financing round, which included one new investor, Perceptive Advisors, along with current investors Gilde Healthcare Partners, Morgenthaler Ventures, QuestMark Partners, Kaiser Permanente, Adage Capital Management, Crestline Investors and Cross Creek Capital.

“We are delighted by our investors’ continued support of Vapotherm. Their support helps us provide High Flow Therapy, our unique respiratory solution to improve clinical and economic outcomes for customers and the patients they serve,” said Joe Army, President and CEO of Vapotherm.

Tony Arnerich, CEO of Arnerich Massena, commented “We are enthusiastic about continuing to support Vapotherm. This new capital will help the company continue the expansion of the U.S. field organization, develop new products and expand in select International markets.”

Vapotherm, Inc. is a privately held developer and manufacturer of advanced respiratory care technology based in Exeter, New Hampshire. The company develops innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 700,000 patients have been treated with Vapotherm High Flow Therapy. For more information, visit www.vtherm.com.

Contact: John Landry, VP & CFO
T: (603) 658-0011

ProVerum raises €30M in Series A funding led by Gilde Healthcare & Lightstone Ventures

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the closing of a €30 million Series A equity financing led...
January 11, 2022

Gilde Healthcare portfolio Volta Medical treats first U.S. patients with persistent cardiac arrythmias

Volta Medical, a pioneering health tech company developing artificial intelligence (AI)-based software solutions to treat cardiac arrythmias, today announced the introduction of its leading-edge product, VX1, at three leading U.S. hospitals. New York Presbyterian Queens,...
December 21, 2021

Philips acquires Gilde portfolio company Vesper Medical to further expand its image-guided therapy devices portfolio

Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has signed an agreement to acquire Vesper Medical Inc., a US-based medical technology company that develops minimally-invasive peripheral vascular devices....
December 14, 2021